Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients
| Autor: | Mathilde S. L. Jakobsen, Louise Vedtofte, Ole Schjerning, Jens J. Holst, Camilla K Svensson, Jimmi Nielsen, Anders Fink-Jensen, Claus Thorn Ekstrøm, Christoph U. Correll, Sabine Bahn, Tina Vilsbøll, Julie R. Larsen, Hans R. Jespersen, Kamuran Koyuncu, Michelle I Jakobsen, Jakub Tomasik, Nitin Rustogi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Olanzapine medicine.medical_specialty prediabetes Carbohydrate metabolism 03 medical and health sciences 0302 clinical medicine Internal medicine OGTT medicine Prediabetes Clozapine Glucagon-like peptide 1 receptor liraglutide adiponectin Adiponectin Liraglutide business.industry Leptin GLP-1RA medicine.disease Psychiatry and Mental health 030104 developmental biology Endocrinology biomarker business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Tomasik, J, Rustogi, N, Larsen, J R, Jakobsen, M I, Svensson, C K, Vedtofte, L, Jakobsen, M S L, Jespersen, H R, Koyuncu, K, Schjerning, O, Nielsen, J, Ekstrøm, C T, Correll, C U, Holst, J J, Vilsbøll, T, Bahn, S & Fink-Jensen, A 2020, ' Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine-or Olanzapine-Treated, Prediabetic, Schizophrenia Patients ', Schizophrenia Bulletin Open, vol. 1, no. 1, sgaa044 . https://doi.org/10.1093/schizbullopen/sgaa044 |
| ISSN: | 2632-7899 |
| DOI: | 10.1093/schizbullopen/sgaa044 |
| Popis: | Background We previously demonstrated that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide significantly reduced glucometabolic disturbances and body weight vs placebo in prediabetic, overweight, or obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. Here, we aimed to identify potential biomarkers of prediabetes and the GLP-1RA-induced effects on glucose tolerance in schizophrenia patients treated with clozapine or olanzapine. Methods Multiplexed immunoassays were used to measure 8 proteins (adiponectin, C-reactive protein, interleukin-1 receptor antagonist, leptin, macrophage migration inhibitory factor, prolactin, receptor for advanced glycation end products, and vascular endothelial growth factor [VEGF]) in fasting prediabetic and non-prediabetic patients with schizophrenia-spectrum disorder, the prediabetic patients receiving 16-week randomized treatment with liraglutide or placebo. Results Serum adiponectin (P = .004) and VEGF (P = .019) levels were significantly lower in prediabetic (n = 81) than non-prediabetic schizophrenia-spectrum disorder patients (n = 32). Adiponectin levels increased significantly (P = .022) and leptin levels decreased significantly (P = .017) following treatment with liraglutide (n = 39) vs placebo (n = 42). Importantly, patients receiving liraglutide who had higher baseline leptin levels showed significantly larger reductions in the primary endpoint, the 75-g oral glucose tolerance test value, than patients with lower baseline leptin levels (P = .009). Conclusion These results provide new evidence for metabolic alterations associated with prediabetes and GLP-1RA treatment in the context of schizophrenia. They suggest that leptin may be a valuable biomarker predicting GLP-1RA-induced improvement in glucose tolerance in overweight or obese schizophrenia-spectrum disorder patients with prediabetes treated with clozapine or olanzapine. These findings require further validation in larger numbers of individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|